Intellia Therapeutics (NTLA) Reaches $16.31 After 4.00% Down Move; Greenbrier Companies (GBX) Shorts Down By 1.61%

June 29, 2017 - By Stephen Andrade

Greenbrier Companies Incorporated (NYSE:GBX) had a decrease of 1.61% in short interest. GBX’s SI was 8.96M shares in June as released by FINRA. Its down 1.61% from 9.11 million shares previously. With 462,800 avg volume, 19 days are for Greenbrier Companies Incorporated (NYSE:GBX)’s short sellers to cover GBX’s short positions. The SI to Greenbrier Companies Incorporated’s float is 33.05%. About 299,157 shares traded. Greenbrier Companies Inc (NYSE:GBX) has risen 66.79% since June 29, 2016 and is uptrending. It has outperformed by 50.09% the S&P500.

The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) is a huge mover today! About 153,129 shares traded. Intellia Therapeutics Inc (NASDAQ:NTLA) has declined 46.16% since June 29, 2016 and is downtrending. It has underperformed by 62.86% the S&P500.The move comes after 8 months negative chart setup for the $624.31M company. It was reported on Jun, 29 by Barchart.com. We have $15.66 PT which if reached, will make NASDAQ:NTLA worth $24.97M less.

The Greenbrier Companies, Inc. is a designer, maker and marketer of railroad freight car equipment in North America and Europe; a maker and marketer of marine barges in North America; a well-known provider of wheel services, parts, leasing and other services to the railroad and related transportation industries in North America, and a well-known provider of railcar repair, refurbishment and retrofitting services in North America through a joint venture partnership. The company has market cap of $1.39 billion. It operates in four divisions: Manufacturing; Wheels & Parts; Leasing & Services, and GBW Joint Venture. It has a 12.01 P/E ratio. It also produces rail castings and tank heads through unconsolidated joint ventures.

Among 11 analysts covering Greenbrier Companies (NYSE:GBX), 2 have Buy rating, 3 Sell and 6 Hold. Therefore 18% are positive. Greenbrier Companies had 18 analyst reports since September 2, 2015 according to SRatingsIntel. The company was downgraded on Wednesday, October 19 by Standpoint Research. Cowen & Co maintained Greenbrier Companies Inc (NYSE:GBX) on Tuesday, January 10 with “Outperform” rating. The rating was downgraded by Longbow on Monday, June 20 to “Neutral”. As per Tuesday, December 15, the company rating was initiated by Standpoint Research. The company was maintained on Friday, April 7 by Cowen & Co. The rating was downgraded by BBT on Thursday, March 17 to “Hold”. The company was maintained on Wednesday, April 6 by Avondale. Cowen & Co initiated Greenbrier Companies Inc (NYSE:GBX) rating on Monday, December 14. Cowen & Co has “Outperform” rating and $41 target. The firm earned “Underperform” rating on Tuesday, January 3 by Longbow. The company was downgraded on Wednesday, October 26 by Bank of America.

Since January 6, 2017, it had 0 insider buys, and 10 insider sales for $18.92 million activity. FURMAN WILLIAM A also sold $5.50 million worth of Greenbrier Companies Inc (NYSE:GBX) shares. Shares for $464,121 were sold by BAKER MARTIN RAYMOND on Tuesday, April 11. Centurion Alejandro also sold $384,800 worth of Greenbrier Companies Inc (NYSE:GBX) on Monday, April 10. RITTENBAUM MARK J sold $279,693 worth of stock or 6,250 shares.

Investors sentiment decreased to 1.1 in Q4 2016. Its down 0.39, from 1.49 in 2016Q3. It fall, as 29 investors sold Greenbrier Companies Inc shares while 64 reduced holdings. 40 funds opened positions while 62 raised stakes. 28.00 million shares or 2.73% more from 27.25 million shares in 2016Q3 were reported. Financial Bank Of Montreal Can owns 0.01% invested in Greenbrier Companies Inc (NYSE:GBX) for 156,869 shares. First Quadrant Limited Partnership Ca owns 45,980 shares or 0.04% of their US portfolio. Paloma Prns invested in 0% or 10,500 shares. Moreover, Deutsche Bancorporation Ag has 0.01% invested in Greenbrier Companies Inc (NYSE:GBX) for 290,148 shares. State Of Tennessee Treasury Department holds 0% of its portfolio in Greenbrier Companies Inc (NYSE:GBX) for 21,587 shares. Hgk Asset Mngmt reported 19,932 shares. 47,751 are owned by Dupont Cap Management. Louisiana State Employees Retirement System has 0.02% invested in Greenbrier Companies Inc (NYSE:GBX). Adams Diversified Equity Fund Incorporated holds 0.08% of its portfolio in Greenbrier Companies Inc (NYSE:GBX) for 29,500 shares. Putnam Investments Ltd Liability Co holds 100,256 shares or 0.01% of its portfolio. Morgan Stanley accumulated 838,568 shares. Royal State Bank Of Canada holds 1.20 million shares or 0.03% of its portfolio. Parkside Fincl Financial Bank owns 0% invested in Greenbrier Companies Inc (NYSE:GBX) for 17 shares. Invesco has 0% invested in Greenbrier Companies Inc (NYSE:GBX) for 95,492 shares. Moreover, Raymond James Finance Svcs Advisors Inc has 0% invested in Greenbrier Companies Inc (NYSE:GBX).

Intellia Therapeutics, Inc. is a genome editing company. The company has market cap of $624.31 million. The Firm is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. It currently has negative earnings. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence.

Among 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intellia Therapeutics has $39 highest and $33 lowest target. $36’s average target is 120.72% above currents $16.31 stock price. Intellia Therapeutics had 5 analyst reports since May 31, 2016 according to SRatingsIntel. Credit Suisse initiated Intellia Therapeutics Inc (NASDAQ:NTLA) rating on Tuesday, May 31. Credit Suisse has “Outperform” rating and $39 target. The rating was upgraded by Leerink Swann on Friday, August 5 to “Outperform”. The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) has “Buy” rating given on Friday, August 5 by Jefferies. Jefferies initiated Intellia Therapeutics Inc (NASDAQ:NTLA) on Tuesday, May 31 with “Hold” rating. On Tuesday, May 31 the stock rating was initiated by Wedbush with “Outperform”.

Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on August, 3. They expect $-0.37 EPS, down 2.78% or $0.01 from last year’s $-0.36 per share. After $-0.36 actual EPS reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.78% negative EPS growth.